Contributions
Abstract: S113
Type: Oral Presentation
Presentation during EHA22: On Friday, June 23, 2017 from 12:15 - 12:30
Location: Hall C
Background
Despite up-to-date risk algorithms, outcome in acute myeloid leukemia patients is still difficult to predict. Even in good risk patients relapses occur. Further refinement of currently used risk classifications is therefore warranted.
Aims
In this study we used data of the HOVON/SAKK H102 trial to prospectively define, using flow cytometry, the leukemic CD34+CD38- stem cell frequencies and MRD frequencies to investigate impact on patient outcome.
Methods
In 242 patients who achieved morphologic complete remission, both LSC and MRD data after two cycles of chemotherapy treatment were available. MRD-positivity was defined as a percentage of MRD-positive cells above 0.1% (as compared to total amount of WBCs) and LSC-positivity was defined as a CD34+CD38-LSC percentage above 0.0000% (LSC cut-off 0.0000%; thus no CD34+CD38-LSC events measured).
Results
Cumulative incidence of relapse (CIR) and overall survival (OS) data were investigated for four different MRD/LSC groups: 1. MRDneg + LSCneg patients (n=136) 2. MRDpos + LSCneg patients (n=28) 3. MRDneg + LSCpos patients (n=58) and 4. MRDpos + LSCpos patients (n=20). Results showed that MRDpos + LSCpos patients have the worst prognosis.
Conclusion
Overall, we conclude that our prospective results show that CD34+CD38-LSC frequency has important additional value in MRD assessment and that it especially enables to identify very poor risk patients in all different currently used risk categories. These data urge to include both MRD and LSC in future AML risk classification to better inform post-remission treatment.
Session topic: 4. Acute myeloid leukemia - Clinical
Keyword(s): Acute Myeloid Leukemia, prognosis, Minimal residual disease (MRD), Leukemic Stem Cell
Abstract: S113
Type: Oral Presentation
Presentation during EHA22: On Friday, June 23, 2017 from 12:15 - 12:30
Location: Hall C
Background
Despite up-to-date risk algorithms, outcome in acute myeloid leukemia patients is still difficult to predict. Even in good risk patients relapses occur. Further refinement of currently used risk classifications is therefore warranted.
Aims
In this study we used data of the HOVON/SAKK H102 trial to prospectively define, using flow cytometry, the leukemic CD34+CD38- stem cell frequencies and MRD frequencies to investigate impact on patient outcome.
Methods
In 242 patients who achieved morphologic complete remission, both LSC and MRD data after two cycles of chemotherapy treatment were available. MRD-positivity was defined as a percentage of MRD-positive cells above 0.1% (as compared to total amount of WBCs) and LSC-positivity was defined as a CD34+CD38-LSC percentage above 0.0000% (LSC cut-off 0.0000%; thus no CD34+CD38-LSC events measured).
Results
Cumulative incidence of relapse (CIR) and overall survival (OS) data were investigated for four different MRD/LSC groups: 1. MRDneg + LSCneg patients (n=136) 2. MRDpos + LSCneg patients (n=28) 3. MRDneg + LSCpos patients (n=58) and 4. MRDpos + LSCpos patients (n=20). Results showed that MRDpos + LSCpos patients have the worst prognosis.
Conclusion
Overall, we conclude that our prospective results show that CD34+CD38-LSC frequency has important additional value in MRD assessment and that it especially enables to identify very poor risk patients in all different currently used risk categories. These data urge to include both MRD and LSC in future AML risk classification to better inform post-remission treatment.
Session topic: 4. Acute myeloid leukemia - Clinical
Keyword(s): Acute Myeloid Leukemia, prognosis, Minimal residual disease (MRD), Leukemic Stem Cell